Cambia - Recently Approved Drug by FDA

Generic Name : diclofenac potassium for oral solutionDate of Approval: June 17, 2009

The U.S. Food and Drug Administration (FDA) has approved Cambia, a diclofenac-based non-steroidal anti-inflammatory drug ("NSAID") combined with potassium bicarbonate, for the treatment of acute migraine with or without aura in adults.
Cambia, formulated with KPA's patented Dynamic Buffering Technology (DBT), was specifically developed to address widespread unmet needs among patients by offering fast and effective relief of migraine pain. In randomized clinical trials, Cambia was shown to be effective not only in migraine pain, but also in treating photophobia (sensitivity to light), phonophobia (sensitivity to sound), and nausea commonly associated with migraine attacks. It was also shown to provide statistically significant onset of relief of migraine pain within 15 to 30 minutes.

Link: http://www.drugs.com/cambia.html